Andrea Berry, MD

• Columbia College, B.A., Biochemistry, 1998
• University of Pennsylvania School of Medicine, M.D., 2003
• Residency, The Children's Hospital of Philadelphia, Pediatrics, 2003-2006
• Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases, 2006-2009
• University of Maryland, Baltimore, M.S., Epidemiology and Clinical Research, 2023

Dr. Berry is a board-certified pediatric infectious disease specialist with an interest in malaria immunology and pediatric vaccine trials. She co-leads the Malaria Immunology Unit within the Malaria Research Program, where she studies the humoral immune response to malaria following natural infection and malaria vaccination. Dr. Berry conducts malaria vaccine trials and challenge studies at the University of Maryland Center for Vaccine Development and Global Health (CVD).

Dr. Berry is a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine and Treatment Evaluation Unit (VTEU) network of investigators. Recent NIAID clinical studies have included trials of COVID-19 vaccines, pandemic and seasonal influenza vaccines, a study of concurrent use of both licensed brands of rotavirus vaccines within the same schedule, and a study of the immunogenicity of Human Papilloma Virus vaccine when given outside of the recommended schedule.

Malaria, clinical vaccine trials, immunology.

Berry AA, Tjaden AH, Renteria J, Friedman-Klabanoff D, Hinkelman AN, Gibbs MA, Ahmed A, Runyon MS, Schieffelin J, Santos RP, Oberhelman R, Bott M, Correa A, Edelstein SL, Uschner D, Wierzba TF. Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership. Vaccine X. 2023 Dec;15:100371. doi: 10.1016/j.jvacx.2023.100371. eCollection 2023 Dec. PubMed PMID: 37649617; PubMed Central PMCID: PMC10462856.

Datar R, Fette LM, Hinkelman AN Hammershaimb EA, Friedman-Klabanoff DJ, Mongraw-Chaggin M, Weintraub WS, Ahmed N, Gibbs MA, Runyon MS, Plumb ID, Thompson W, Saydah S, Edelstein SL, Berry AA, for the COVID-19 Community Research Partnership. Factors associated with COVID-19 vaccination during June–October, 2021: a multi-site prospective study. Vaccine. 3/31/2023, Epub ahead of print, PMID: 37069033 PMCID: PMC10063571.

Berry AA*, Obiero JM*, Travassos MA, Ouattara A, Coulibaly D, Adams M, Jain A, Taghavian O, Sy A, Nakajima R, Jasinskas A, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Sim KL, Hoffman SL, Plowe CV, Thera MA, Felgner PL‡, and Lyke KE‡. Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. *contributed equally, ‡contributed equally. NPJ Vaccines 2021 Sep 13;6(1):115. doi: 10.1038/s41541-021-00363-y. PMID: 34518543 PMCID: PMC8438027

Friedman-Klabanoff DJ, Travassos MA, Ifeonu OO, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA.Epitope-specific antibody responses to a Plasmodium falciparum subunit vaccine target in a malaria-endemic population. J Infect Dis. 2020 Sep 29;. doi: 10.1093/infdis/jiaa611.[Epub ahead of print]PubMed PMID: 32992328.

Berry AA, Yang Y, Pakharukova N, Garnett JA, Lee W, Cota E, Marchant J, Roy S, Tuittila M, Liu B, Inman KG, Ruiz-Perez F, Mandomando I, Nataro JP, Zavialov AV, Matthews S.  Structural insight into host recognition by aggregative adherence fimbriae of enteroaggregative Escherichia coli. PLoS Pathogens. 2014 Sep 18;10(9):e1004404.

View a complete list of Dr. Berry's publications.